Phase 3 Readout~month

Phase 3 Topline: A Phase 3 Randomized, Double-Blind, Placebo-Controlled, 78-Week Efficacy and Safety Study of VK2735

Drug
vk2735
Indication
Weight Loss

Other upcoming events for VKTX

Patent ExpiryPatent/Exclusivity Expiry: DUEXIS

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 3 Topline: A Phase 3 Randomized, Double-Blind, Placebo-Controlled, 78-Week Efficacy and Safety Study of VK2735 — VKTX Phase 3 Readout | BioSniper